General AML

The FDA grants GMI-1271 Breakthrough Therapy Designation for the treatment of R/R AML

On 17th March 2017, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to GMI-1271, a novel E-selectin (E-sel) antagonist , for the treatment of patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML).1

E-sel is a cell adhesion molecule expressed constitutively in the bone marrow endothelium and it is involved in cell signaling and chemotaxis. Binding of AML blasts to E-selectin (E-sel), can lead to activation of leukemic cell survival pathways, thereby contributing to chemotherapy resistance. GMI-1271 is a novel antagonist of E-sel, which acts by disrupting leukemia cell survival pathways thus enhancing chemotherapy response.2,3

Currently, GMI-1271 is being explored in the phase 2 portion of the phase 1/2 study (NCT02306291), which is aiming to assess the safety, efficacy and pharmacokinetics of this agent in combination with standard chemotherapy in patients with R/R AML and also in AML patients 60 years of age and older with newly diagnosed disease.

  1. GlycoMimetics: GMI-1271 Receives FDA Breakthrough Therapy Designation for Adult Relapsed/Refractory Acute Myeloid Leukemia. 2017 May 17. [Accessed 2017 May 18].
  2. National Cancer Institute: E-selectin antagonist GMI-1271. [Accessed 2017 May 18].
  3. DeAngelo D. J. et al. A Phase I/II Study of GMI-1271, a Novel E-Selectin Antagonist, in Combination with Induction Chemotherapy in Relapsed/Refractory and Elderly Previously Untreated Acute Myeloid Leukemia; Results to Date. 2016 Dec 5. Abstract 2029. 58th Annual Meeting of the American Society of Hematology, San Diego, Ca.
Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF